This transgene consists of the human wild-type alpha-synuclein cDNA under the control of the tetracycline responsive promoter. Alpha-synuclein is expressed only in the presence of the tetracycline transactivator (tTA), expressed from a second transgene; administration of doxycycline inhibits tTA binding to tetO, thus suppressing alpha-synuclein expression. (J:156801)